Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ANAPTYSBIO, INC (ANAB)
|
Add to portfolio |
|
|
|
| Price: |
$35.94
| | Metrics |
| OS: |
26.5
|
M
| |
-30
|
% ROE
|
| Market cap: |
$954
|
M
| |
-32
|
% ROIC
|
|
Net cash:
|
$489
|
M
| |
$18.41
|
per share
|
|
EV:
|
$465
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($139)
|
M
| |
|
|
|
EBIT
|
($140)
|
M
| |
|
|
| EPS |
($5.20)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 10.3 | 63.2 | 75.0 | 8.0 | 5.0 | 10.0 | 16.7 | 17.6 |
| Revenue growth | -83.7% | -15.8% | 837.5% | 60.0% | -50.0% | -40.1% | -5.0% | 104.0% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 10.3 | 63.2 | 75.0 | 8.0 | 5.0 | 10.0 | 16.7 | 17.6 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research and development | 88.8 | 98.5 | 80.0 | 99.3 | 56.2 | 29.4 | 15.4 | 17.3 |
| General and administrative | 36.6 | 21.5 | 18.9 | 16.1 | 15.5 | 9.3 | 4.3 | 3.6 |
| EBIT | -115.2 | -56.8 | -23.9 | -107.4 | -66.7 | -28.8 | -3.0 | -3.3 |
| EBIT margin | -1119.4% | -89.9% | -31.8% | -1342.9% | -1334.4% | -287.8% | -18.1% | -18.9% |
| Pre-tax income | -128.7 | -57.8 | -19.9 | -97.5 | -61.8 | -30.1 | -4.3 | -5.3 |
| Income taxes | 0.0 | 0.0 | 0.0 | -0.2 | -0.2 | 0.0 | 0.0 | 0.1 |
| Tax rate | | 0.0% | 0.0% | 0.2% | 0.3% | 0.0% | 0.0% | |
| Net income | -128.7 | -57.8 | -19.9 | -97.3 | -61.7 | -30.1 | -4.3 | -5.4 |
| Net margin | -1251.3% | -91.5% | -26.6% | -1216.7% | -1233.1% | -300.7% | -25.5% | -30.8% |
| |
| Diluted EPS | ($4.57) | ($2.11) | ($0.73) | ($3.60) | ($2.50) | ($1.52) | ($1.62) | ($2.12) |
| Shares outstanding (diluted) | 28.2 | 27.4 | 27.3 | 27.1 | 24.7 | 19.8 | 2.6 | 2.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|